bDMARDs, including TNF inhibitors (etanercept, infliximab, adalimumab), IL-6 inhibitors (tocilizumab), B-cell-depleting agents (rituximab), and T-cell co-stimulation blockers (abatacept), have significantly advanced RA management [72]. This evidence concerns the gene IL6 and rheumatoid arthritis.